High levels of VEGF were observed in previous studies and anti-VEDF therapy proposed to control COVID-19 in critically ill patients (36), especially those with gastrointestinal symptoms correlated with intestinal edema and disease progression (37). The gene discussed is VEGFA; the disease is COVID-19.